CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting

CVRx (NASDAQ: CVRX) announced scientific presentations and late-breaking clinical data on Barostim at THT 2026, March 2-4 in Boston.

Rhea-AI Summary

CVRx (NASDAQ: CVRX) announced scientific presentations and late-breaking clinical data on Barostim at THT 2026, March 2-4 in Boston. Key items include six-month outcomes from the REBALANCE Registry in over 400 patients, updates from BREATHE-HF, and initiation of the BENEFIT-HF trial.

The company will host a satellite program March 3, 12:15-1:30 p.m. ET, and said BENEFIT-HF has CMS Category B IDE coverage with enrollment expected to begin in the first half of 2026.

Positive

• REBALANCE Registry: six-month outcomes in over 400 patients
• BENEFIT-HF: trial initiated with CMS Category B IDE coverage; enrollment expected H1 2026
• Late-breaking data: Barostim featured in THT 2026 scientific sessions and posters

Negative

• None.

Argus Mar 2 session

+0.74% close to close Open Argus

Details

News Market Reaction – CVRX

On Mar 2, the day this news came out, CVRX closed 0.74% above the previous close.

Data tracked by StockTitan Argus for the Mar 2 session.

Key Figures

REBALANCE Registry follow-up: six-month outcomes REBALANCE Registry size: over 400 patients THT 2026 dates: March 2–4, 2026 +2 more

REBALANCE Registry follow-up

six-month outcomes

Initial six-month outcomes with Barostim in REBALANCE Registry

REBALANCE Registry size

over 400 patients

Post-market observational REBALANCE Registry enrollment

THT 2026 dates

March 2–4, 2026

Technology and Heart Failure Therapeutics 2026 meeting schedule

Satellite program time

12:15–1:30 p.m. ET

CVRx-sponsored satellite program on March 3 at THT 2026

BENEFIT-HF enrollment start

first half of 2026

Enrollment for BENEFIT-HF trial expected timing

Historical Context

5 past events · Latest: Feb 12

5 events

1. Feb 12

   Q4/FY25 earnings

   24h Move

   -13.0%

   Reported FY25 revenue of $56.7M with 85% gross margin and 2026 guidance.

2. Jan 29

   Earnings call date

   24h Move

   -2.3%

   Announced timing and access details for Q4 2025 earnings call and webcast.

3. Jan 22

   BENEFIT-HF initiation

   24h Move

   +11.4%

   Initiated BENEFIT-HF randomized trial in expanded heart failure population.

4. Jan 12

   Prelim results/guidance

   24h Move

   -9.9%

   Issued preliminary FY25 revenue ranges and 2026 guidance with updated costs.

5. Jan 06

   Reimbursement update

   24h Move

   +3.3%

   Confirmed implementation of Category I CPT codes for Barostim therapy.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

neuromodulation, barostim, baroreflex activation therapy, left ventricular ejection fraction, +4 more

8 terms

neuromodulation medical

"a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

barostim medical

"presentations reviewing the science and outcomes of Barostim therapy at the Technology and Heart Failure Therapeutics 2026"

Barostim is an implantable medical device that sends mild electrical pulses to sensors in the neck (baroreceptors) to help the body lower and stabilize blood pressure and reduce strain on the heart. Think of it like a thermostat for blood pressure: when readings are too high, the device nudges the body's natural braking system, and investors care because its clinical effectiveness, regulatory approvals, and insurance coverage determine how widely it can be adopted and how much revenue the technology can generate.

baroreflex activation therapy medical

"Initial Six-Month Outcomes with Baroreflex Activation Therapy from the REBALANCE Registry"

An implantable device therapy that sends gentle electrical signals to the body’s blood‑pressure sensors to trigger a natural reflex that lowers blood pressure and eases strain on the heart—think of it like a thermostat that nudges the body to steady its pressure. It matters to investors because its commercial success depends on clinical effectiveness, regulatory clearance, reimbursement and adoption, which together determine the size and predictability of device sales and follow‑on service revenue.

left ventricular ejection fraction medical

"highlighting real-world outcomes, cardiac energetics, hospitalization impact, left ventricular ejection fraction (LVEF) improvements"

Left ventricular ejection fraction (LVEF) is the percentage of blood the heart’s main pumping chamber pushes out with each beat, measured by comparing the volume before and after contraction. Think of it as how much water a pump empties from a tank each cycle — higher percentages mean stronger pumping. Investors care because LVEF is a common clinical measure that affects patient outcomes, market size for treatments, trial success, reimbursement and regulatory decisions in healthcare-related investments.

lvef medical

"left ventricular ejection fraction (LVEF) improvements and changes in advanced hemodynamic, respectively."

Left ventricular ejection fraction (LVEF) is a percentage that measures how much blood the heart’s main pumping chamber pushes out with each beat, like the share of water a pump empties from a bucket each cycle. Investors watch LVEF because it’s a key medical yardstick used to diagnose and track heart function, shaping demand for drugs, devices, clinical trials, insurance costs and the financial outlook of healthcare-related businesses.

hemodynamic medical

"changes in advanced hemodynamic, respectively. Late-Breaking REBALANCE Registry Data"

Relating to blood flow and the forces that move it through the body, hemodynamic describes how blood pressure, volume and circulation behave in vessels and organs. Investors pay attention because changes in hemodynamics are key measures of whether a drug, device or procedure is safe and effective—think of it like plumbing and traffic: blockages or pressure spikes can signal big risks or benefits that affect a product’s regulatory approval, market adoption and reimbursement.

cms category b ide coverage regulatory

"a landmark randomized study supported by CMS Category B IDE coverage."

CMS Category B IDE coverage is a Medicare policy that determines when Medicare will pay for routine care and certain costs tied to clinical trials of investigational medical devices operating under an Investigational Device Exemption (IDE). For investors, this matters because CMS coverage decisions influence patient access and trial enrollment, which can speed or slow a device maker’s path to market and future revenue — like whether a bridge is open for traffic, affecting how quickly goods can move.

randomized study medical

"BENEFIT-HF trial, a landmark randomized study supported by CMS Category B IDE coverage."

A randomized study is an experiment in which people, groups, or other units are assigned by chance to different treatments or approaches so the results reflect the effect of the treatment rather than other factors. For investors, randomized studies carry more credible evidence about whether a drug, device, business change, or strategy actually works—think of it as a fair coin flip that helps separate true results from luck or bias, reducing uncertainty about future returns or risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations reviewing the science and outcomes of Barostim therapy at the Technology and Heart Failure Therapeutics 2026 (THT) meeting. THT, the annual conference organized by the Cardiovascular Research Foundation® (CRF®), will be held March 2-4, 2026, in Boston, Massachusetts.

The presentations include late-breaking clinical data, oral sessions and posters highlighting real-world outcomes, cardiac energetics, hospitalization impact, left ventricular ejection fraction (LVEF) improvements and changes in advanced hemodynamic, respectively. 

Late-Breaking REBALANCE Registry Data

In a late-breaking presentation on Monday, March 2, Dr. Dmitry Yaranov will share, for the first time, data from the REBALANCE Registry, a post-market observational study designed to evaluate real-world data on the safety and benefit of Barostim therapy in the commercial setting. Dr. Yaranov will present the six-month outcomes in over 400 patients enrolled in the registry.

Scientific Presentations Featuring Barostim

Monday, March 2:

• Late-Breaking Clinical Science Session 1: Initial Six-Month Outcomes with Baroreflex Activation Therapy from the REBALANCE Registry (Dr. Dmitry Yaranov)
• Unmasking the Energetic Response Following Acute Titration of Baroreflex Activation Therapy Through Patient-Specific Modeling and Simulation (Dr. Rohan Goswami)
• Impact of Baroreflex Activation Therapy on Hospitalizations: A Single Center Retrospective Analysis (Dr. Joel Joseph)
  

Tuesday, March 3:

• Electrical Therapies for Heart Failure: Barostimulation for HFrEF (Dr. Philip Adamson)
• Abstract Session 8: Heart Failure Reduced Ejection Fraction I
  • Real-World Outcomes of Barostim Baroreflex Activation Therapy in Heart Failure: Analysis of a Large Multi-Institutional Database (Dr. Arvind Bhimaraj)
  • LVEF and Functional Improvement Observed in a Post-Market Registry of Barostim Baroreflex Activation Therapy (Dr. Dmitry Yaranov)

CVRx Sponsored Satellite Program

CVRx will also host a satellite program on Tuesday, March 3 from 12:15-1:30 p.m. ET in Ensemble CD South, which will include the following presentations:

• Advances in Evidence with Baroreflex Activation Therapy (Dr. Philip Adamson)
• Outcomes from the REBALANCE Registry (Dr. Dmitry Yaranov)
• BREATHE-HF: Impact of Barostim Therapy on Cardiac Hemodynamics
  (Dr. Gabriel T. Sayer)
• BENEFIT-HF: Broadening Access to Barostim Therapy (Dr. Farooq Sheikh)
  

During the satellite program, faculty will provide updates on the REBALANCE Registry, the BREATHE-HF trial, and the BENEFIT-HF trial. BREATHE-HF, a large physician-initiated study, is evaluating the impact of Barostim on cardiac hemodynamics. In January, CVRx announced the initiation of the BENEFIT-HF trial, a landmark randomized study supported by CMS Category B IDE coverage. The trial is designed to evaluate the impact of Barostim in a significantly expanded heart failure population, with the primary endpoint as a composite of all-cause mortality and heart failure decompensation events. Enrollment is expected to begin in the first half of 2026.

“We are excited by the new data supporting Barostim being featured at THT 2026,” said Kevin Hykes, President and Chief Executive Officer of CVRx. “We are encouraged by the increasing adoption of Barostim by the heart failure community. The accelerating cadence of publications evaluating Barostim’s impact is proof of the positive patient impact and increasing acceptance of Barostim in the heart failure treatment continuum.”

About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the expected enrollment of the BENEFIT-HF clinical trial and anticipated benefits of Barostim therapy. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our expectations regarding enrollment, the resulting impact of our addressable market and other important factors that could cause actual results, performance or achievements to differ materially from those that are found in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com

Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What REBALANCE Registry results did CVRx (CVRX) present at THT 2026?

CVRx presented six-month outcomes from the REBALANCE Registry in over 400 patients. According to the company, this was the first public presentation of post-market real-world safety and benefit data for Barostim in a commercial setting.

When and where will CVRx present late-breaking Barostim data at THT 2026?

CVRx presentations occur at THT 2026 in Boston, March 2-4, 2026. According to the company, the late-breaking clinical science session including REBALANCE data was scheduled for Monday, March 2.

What is the BENEFIT-HF trial announcement from CVRx (CVRX)?

BENEFIT-HF is a randomized trial supported by CMS Category B IDE, with enrollment expected to begin in the first half of 2026. According to the company, the trial will assess a composite endpoint of all-cause mortality and heart failure decompensation events.

What topics are covered in the CVRx satellite program at THT 2026?

The CVRx satellite program on March 3, 12:15-1:30 p.m. ET covers REBALANCE updates, BREATHE-HF hemodynamics, BENEFIT-HF access, and advances in evidence for Barostim. According to the company, invited faculty will present those study updates.

What is the BREATHE-HF study update CVRx reported at THT 2026?

BREATHE-HF is a large physician-initiated study evaluating Barostim impact on cardiac hemodynamics. According to the company, BREATHE-HF updates were included in the satellite program and scientific sessions at THT 2026.

How large was the patient sample CVRx reported from the REBALANCE Registry?

CVRx reported six-month outcomes in a REBALANCE Registry cohort of over 400 patients. According to the company, this reflects post-market, real-world data collected in the commercial setting.